Supernus Pharmaceuticals (SUPN) EBT: 2011-2025
Historic EBT for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$58.0 million.
- Supernus Pharmaceuticals' EBT fell 228.95% to -$58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.7 million, marking a year-over-year decrease of 128.61%. This contributed to the annual value of $97.9 million for FY2024, which is 3434.49% up from last year.
- As of Q3 2025, Supernus Pharmaceuticals' EBT stood at -$58.0 million, which was down 447.68% from $16.7 million recorded in Q2 2025.
- In the past 5 years, Supernus Pharmaceuticals' EBT registered a high of $44.9 million during Q3 2024, and its lowest value of -$58.0 million during Q3 2025.
- In the last 3 years, Supernus Pharmaceuticals' EBT had a median value of $9.0 million in 2023 and averaged $4.9 million.
- As far as peak fluctuations go, Supernus Pharmaceuticals' EBT soared by 2,564.85% in 2024, and later tumbled by 2,499.59% in 2025.
- Over the past 5 years, Supernus Pharmaceuticals' EBT (Quarterly) stood at $2.1 million in 2021, then surged by 1,613.31% to $35.1 million in 2022, then slumped by 97.18% to $990,000 in 2023, then soared by 2,564.85% to $26.4 million in 2024, then tumbled by 228.95% to -$58.0 million in 2025.
- Its EBT stands at -$58.0 million for Q3 2025, versus $16.7 million for Q2 2025 and -$5.8 million for Q1 2025.